starpharma | home
home
about starpharma
technology
 product pipeline
news room
investor relations
 careers contact us
site search
Archive
 
 
 2009
 November 2009
Becoming a Substantial Holder - Orbis Australia
24/11/2009
Cleansing Statement
24/11/2009
Appendix 3B
24/11/2009
Starpharma announces $15.6 million capital raising
18/11/2009
Suspended at the request of company
16/11/2009
Results of Meeting
13/11/2009
AGM Chairman`s and CEO`s Presentations
12/11/2009
Starpharma signs agrochemicals deal
5/11/2009
 October 2009
New legislation results in withdrawal of CEO incentive schem
29/10/2009
Appendix 4C - Quaterly Report
23/10/2009
Notice of Annual General Meeting/Proxy Form
13/10/2009
 September 2009
2009 Annual Report (1.1 MB)
30/09/2009
US Patent Grant Extends VivaGel Coverage to 2024
22/09/2009
Release of Shares From Escrow
18/09/2009
Shareholder Update
17/09/2009
 August 2009
Preliminary Final Report
24/08/2009
Interim Financial Results - Material Improvement
4/08/2009
VivaGel - Anti-HIV and Herpes Activity following Human Admin
3/08/2009
 July 2009
Appendix 4C - Quarterly Report
27/07/2009
 June 2009
Appendix 3B - Employee Share Options
30/06/2009
Lapse of Unquoted Options
30/06/2009
Shareholder Update June 2009
2/06/2009
 May 2009
Change in substantial holding
25/05/2009
Cleansing Statement
22/05/2009
Appendix 3B
22/05/2009
Appendix 3B
22/05/2009
Completes $7.1m capital raising
21/05/2009
CEO Investor Presentation
13/05/2009
Elanco Deal Triggers Starpharma SPP Extension
11/05/2009
Starpharma and Elanco Sign Agreement
11/05/2009
Share Purchase Plan Extension
5/05/2009
 April 2009
Shareholder Update May 2009
30/04/2009
Share Purchase Plan
22/04/2009
Change in Substantial Holding
16/04/2009
Cleansing Statement
8/04/2009
Appendix 3B
8/04/2009
Appendix 4C - Quarterly Report
7/04/2009
Raises Additional Capital via Institutional Placement
7/04/2009
Trading Halt
3/04/2009
 March 2009
Completes patient testing in retention of activity study
19/03/2009
 February 2009
2008 Half Yearly Report and Half Year Accounts (0.2MB)
19/02/2009
Topical Microbicide Field Boost With Efficacy Result
10/02/2009
Lapse of unquoted options
9/02/2009
 January 2009
Appendix 4C - Quarterly Report
30/01/2009

 2008
 December 2008
Appendix 3B Employee and consultant share options
24/12/2008
Lapse of share options
24/12/2008
Starpharma Dendrimer Reduces Toxicity of Cancer Drug
17/12/2008
Shareholder Update December 2008
8/12/2008
SPL7013 activity against all major HPV strains
4/12/2008
 November 2008
Results of Meeting
17/11/2008
AGM Chair Address and CEO Presentation
14/11/2008
 October 2008
Quarterly Cashflow Report
31/10/2008
Key VivaGel Patent Approved in Japan
30/10/2008
Notice of Annual General Meeting/Proxy Form
14/10/2008
Release of shares from escrow and Form 605
1/10/2008
 September 2008
2008 Annual Report (2.5MB)
29/09/2008
CEO Presentation San Francisco Investor Summit
15/09/2008
VivaGel Condom Full Licence Agreement with Durex
9/09/2008
Change of Director Interest Notice R Hazleton
5/09/2008
Change of Director Interest Notice J Raff
5/09/2008
 August 2008
Change of Director Interest Notice Dr J Raff
29/08/2008
Preliminary Final Report
27/08/2008
VivaGel - New Clinical Trial Commences
13/08/2008
 July 2008
Appendix 4C - Quarterly Report
30/07/2008
Change of Director`s Interest Notice
24/07/2008
New Indication for VivaGel - Bacterial Vaginosis Treatment
9/07/2008
 May 2008
Shareholder Update May 2008
21/05/2008
Dr John Raff Change of Director Interest Notice
19/05/2008
Dr John Raff Change of Director Interest Notice
15/05/2008
Starpharma reports positive VivaGel clinical study results
12/05/2008
 April 2008
Appendix 4C - Quarterly Cash Flow Report
28/04/2008
Change of Director`s Interest Notice R Dobinson
24/04/2008
Opes Prime overhang cleared
24/04/2008
Dr John Raff Change of Director`s Interest Notice
23/04/2008
First commercial product launch DNT Priostar dendrimers
22/04/2008
Excellence in Biotech Investment CEO Presentation
21/04/2008
SPL7013 Inhibits Clinically Relevant Strains of HPV
21/04/2008
Dendrimer SPL7013 Potential Application for Arthritis
14/04/2008
Presentation Dendrimers New Opportunities to Treat Diseases
10/04/2008
Mr Peter Bartels Change of Director`s Interest Notice
9/04/2008
Shareholding Subject to Security Lending Arrangements
7/04/2008
Starpharma signs agreement with Unilever
7/04/2008
Release of Shares from Escrow
4/04/2008
 March 2008
Change of Director Interest Notice
27/03/2008
Change of Director Interest Notice
26/03/2008
Change of Directors Interest Notice J Fairley and J Raff
17/03/2008
 February 2008
Becoming a Substantial Holder
29/02/2008
CEO Investor Presentation
26/02/2008
2007 Half Yearly Report and Half Year Accounts (0.4MB)
21/02/2008
Final Director's Interest Notice
12/02/2008
Retirement of Director Prof. Peter Colman
12/02/2008
 January 2008
Appendix C - Quarterly Report
31/01/2008
Shareholder Update January 2008
17/01/2008
Expansion of VivaGel US trial and completion of enrollment in herpes trial
8/01/2008
FDA Warning for N-9 - An Opportunity for Vivagel
2/01/2008

 2007
 December 2007
CEO to present at Healthcare and Life Sciences Conference
4/12/2007
Signs collaborative research agreement with Stiefel Labs Inc
3/12/2007
 November 2007
VivaGel Awarded International Nanotech Award
19/11/2007
Final Director`s Interest Notice
15/11/2007
Appendix 3B
15/11/2007
Audio stream - AGM CEO’s address
15/11/2007
Results of Meeting
15/11/2007
AGM Chair and CEO presentations
15/11/2007
Resignation of Director
8/11/2007
 October 2007
Appendix 3B
31/10/2007
Appendix C - Quarterly Cashflow Report
31/10/2007
Arterial disease imaging agent funding awarded to Starpharma and Baker Heart Research Institute
31/10/2007
CEO Investor Presentations
23/10/2007
SPL and Durex sign co-development agreement for Vivagel Coated Condoms
16/10/2007
Notice of Annual General Meeting/Proxy Form
12/10/2007
Presents at International Herpes Management Forum Meeting
11/10/2007
Release of Shares from Escrow
9/10/2007
 September 2007
2007 Annual Report (2.1 MB)
27/09/2007
Shareholder Update September 07
4/09/2007
 August 2007
Preliminary Final Report
29/08/2007
Cleansing Statement
24/08/2007
Shareholder Letter - Annual Report default options
23/08/2007
Appendix 3B - Share Placement
23/08/2007
Platinum Partners LLC Invests in Starpharma
21/08/2007
Starpharma`s DNT to Develop Water Purification Technology
8/08/2007
 July 2007
Quarterly Cash Flow Report
31/07/2007
Presents Positive Results of Male Study
24/07/2007
Signs Agreement for Condom Coating Application
18/07/2007
U.S. Trial of VivaGel Commences
10/07/2007
Expiry of Options
3/07/2007
 June 2007
CEO Investor Presentations USA
26/06/2007
Merriman Curhan Ford Initiates Coverage of SPHRY
22/06/2007
Change of Director's Interest Notice
12/06/2007
Change of Director's Interest Notice
8/06/2007
 May 2007
Shareholder Update
28/05/2007
Standard & Poor's Initiates Factual Stock Report Coverage
11/05/2007
CEO presentations USA and Europe
8/05/2007
Priostar Dendrimers Improve Fluorescence Properties
7/05/2007
 April 2007
Commitments Test Entity - Third Quarter Report
30/04/2007
Appendix 3B Employee Share Options
19/04/2007
CEO Presentation to Nanobusiness 2007 Conference
16/04/2007
 March 2007
SPL Joins International OTCQX: a new premium market for US OTCs
26/03/2007
SPL's DNT to supply Dendrimer kits to Sigma-Aldrich
23/03/2007
Starpharma information available through S&P listing program
6/03/2007
 February 2007
2006 Half Yearly Report and Half Year Accounts (0.5MB)
23/02/2007
Investor Presentations New York & Boston
21/02/2007
EMD Biosciences siRNA and DNA Agreement
19/02/2007
Shareholder Update
15/02/2007
NIH Funds Further Clinical Development of VivaGel
13/02/2007
Presentation - Biotech Capital Showcase
7/02/2007
VivaGel Clinical Trials Proceeding as Planned
2/02/2007
 January 2007
Quarterly Cash Flow Report
31/01/2007
Appendix 3B
2/01/2007

 2006
 December 2006
Change of Director's Interest Notice
14/12/2006
Initial Director's Interest Notice
1/12/2006
 November 2006
Change of Director's Interest Notice
27/11/2006
Appendix 3B Employee Share Options
17/11/2006
Retired Dow Corning Chairman appointed to Starpharma Board
17/11/2006
Advice of number of shares issued
16/11/2006
Results of AGM
16/11/2006
AGM - Chairman's & CEO's presentation
15/11/2006
VivaGel Market Update
13/11/2006
 October 2006
Quarterly Cash Flow Report
31/10/2006
Notice of initial substantial holder
25/10/2006
US Clinical Trial of VivaGel™ for Genital Herpes Commences
24/10/2006
Notice Under Section 708a
23/10/2006
SPL completes acquisition of US-based Dendritic Nanotechnologies, Inc.
23/10/2006
CEO Presentation to Lux Executive Summit
17/10/2006
Lux Executive Summit - Cambridge, MA
16/10/2006
Notice of AGM
13/10/2006
Form 605 Ceasing to be Substantial Holder
12/10/2006
Presentation to Asia Pacific Life Science Forum
12/10/2006
Appendix 3B
11/10/2006
Appendix 3Y
11/10/2006
Acquisition of DNT - Positioned for growth
10/10/2006
DNT Acquisition Investor Update
9/10/2006
Starpharma to Acquire Dendritic Nanotechnologies, Inc.
4/10/2006
SPL Trading Halt
3/10/2006
 September 2006
Investee company DNT announces NCI contract
28/09/2006
Release of securities under voluntary escrow
26/09/2006
2006 Annual Report (2.9 MB)
26/09/2006
Preliminary Final Report 30 June 06
7/09/2006
Report to Shareholders September 06
7/09/2006
 August 2006
SPL initiates NIH-funded human trial for VivaGel™
24/08/2006
 July 2006
Commitments Test Entity - 4th Quarter Report
28/07/2006
VivaGel™ IND for Genital Herpes trial clears US FDA
19/07/2006
Initial Director's Interest Notice
6/07/2006
Starpharma Appoints New Chief Executive Officer
3/07/2006
 June 2006
IND Lodged With FDA for VivaGel Genital Herpes Trial
26/06/2006
DNT Inc. announces commercial roll out of Priostar dendrimers
20/06/2006
Presentation to Australian Bio-investment Forum
14/06/2006
VivaGel™ is a Potent Contraceptive in Animal Model
14/06/2006
 April 2006
Quarterly Cash Flow Report
27/04/2006
NIH Funds Clinical Development of VivaGel™ for Genital Herpes
20/04/2006
Increasing US Investment Support for Starpharma
6/04/2006
 March 2006
Appendix 4D
9/03/2006
 February 2006
2005 Half Yearly Report and Half Year Accounts (0.7MB)
25/02/2006
Market Update
7/02/2006
 January 2006
Quarterly Cash Flow Report 31 Dec 2005
31/01/2006
VivaGel™ Fast Track Status
9/01/2006
Expiry of Options
6/01/2006

 2005
 December 2005
Change of Directors Interest Notice
23/12/2005
Appendix 3B
22/12/2005
Starpharma Completes A$15 Million Raising
20/12/2005
Results of EGM
16/12/2005
 November 2005
Letter to shareholders re Share Purchase Plan
25/11/2005
AGM Results
17/11/2005
Section 708a Notice
17/11/2005
Appendix 3B - New Issue Announcement
17/11/2005
AGM Presentation
16/11/2005
Notice of Extraordinary General Meeting
15/11/2005
SPL Raises A$15M Through Institutional Placement & SPP
14/11/2005
DNT Receives "Technology Innovation of the Year" Award
11/11/2005
Market Update - Correction
1/11/2005
Appendix 4C - Quarterly Cash Flow Report
1/11/2005
 October 2005
Substantial Shareholder Notice
18/10/2005
Replacement Form - Appendix 3B
14/10/2005
Replacement Page - Annual Report
14/10/2005
Market Update October 2005
14/10/2005
Notice of Annual General Meeting
13/10/2005
Form 603 - Notice of initial substantial holder
12/10/2005
Notification under Section 708A of Corporations Act 2001
11/10/2005
Appendix 3B
11/10/2005
SPL Secures Full Ownership of Core Technology
11/10/2005
DNT Announces Major Collaboration on Dendrimer Based Cancer Detection Technology
11/10/2005
Development of VivaGel™ Accelerated with US$20 Million Funding From NIH
3/10/2005
 September 2005
Annual Report & Annual Review
29/09/2005
Response to Market Speculation
29/09/2005
Response to ASX Query re Share Price
28/09/2005
SPL Investee Company Dimerix Closes Series A Financing
15/09/2005
Preliminary Final Report for Year Ended June 2005
6/09/2005
 August 2005
CEO Presentation to Australian Biotech Expo
8/08/2005
Frost & Sullivan Award
4/08/2005
 July 2005
Quarterly Cash Flow Report
28/07/2005
Appendix 3B - Employee Share Options
14/07/2005
 May 2005
Investee Company DNT, Inc. Announces New Low-cost Nanostructures
19/05/2005
Investee Company Dimerix Bioscience Offered Ausindustry Grant
11/05/2005
 April 2005
Quarterly Cash Flow Report
28/04/2005
Expiry of Options
8/04/2005
Market Update
4/04/2005
SPL to receive up to $5.6M grant for product development
1/04/2005
 March 2005
SPL appoints Jackie Fairley to newly created COO position
30/03/2005
DNT Appoints Dow Chemical Company Licensing Executive to Board of Directors
29/03/2005
Change of Director's Interest Notice
23/03/2005
Change of Director's Interest Notice
21/03/2005
Starpharma Launches New Start-Up Biotechnology Company
16/03/2005
SPL & Industrial Research Ltd Establish JV
3/03/2005
 February 2005
2004 Half Yearly Report and Half Year Accounts (0.4MB)
25/02/2005
Work With Anadis on Respiratory Protection and Biodefense App.
1/02/2005
Investor Update by CEO
1/02/2005
 January 2005
Quarterly Cash Flow Report
31/01/2005
Starpharma ADRs Added to Nanosphere List of Leading Nano Stocks
28/01/2005
DNT, Dow & Starpharma Sign Major Three-way Nanotechnology Deal
27/01/2005
Responding to Article in 'The Age' Newspaper
24/01/2005
Starpharma Completes Level 1 American Depositary Receipts Program
13/01/2005

 2004
 December 2004
Appendix 3B - Employee Incentives
31/12/2004
VivaGel™ in Top 5 Nanotech Breakthroughs of 2004
24/12/2004
Clinical Study Shows Starpharma's VivaGel™ is Safe
16/12/2004
Change of Director's Interest Notice
15/12/2004
 November 2004
Change of Director's Interest Notice
25/11/2004
Constitution of Starpharma Holdings Ltd
23/11/2004
Starpharma to Establish Level 1 American Depositary Receipts Program
17/11/2004
AGM: Chairman's Address and CEO's Presentation
17/11/2004
Results of AGM
17/11/2004
Phase 1 Preliminary Report: Positive Results for VivaGel™
17/11/2004
 October 2004
Appendix 4C  and Commentary
28/10/2004
Notice of Annual General Meeting
15/10/2004
 September 2004
Starpharma to Lead US$5.4M NIH Project for HIV Prevention
30/09/2004
 August 2004
Preliminary Final Report and Full Year Accounts
25/08/2004
Change of Director's Interest (no change of beneficial ownership)
20/08/2004
VivaGel™ Receives FDA Clearance for 3rd Stage Dosing in Phase 1 Trial
3/08/2004
 July 2004
Quarterly Cash Flow Report - Period Ended 30 June 2004
30/07/2004
Appendix 3B - Options
15/07/2004
Change of Director's Interest
14/07/2004
Starpharma Projects Receive ARC Grants
6/07/2004
 June 2004
Starpharma Granted Additional Nanotechnology Patent in USA
7/06/2004
 May 2004
Change in Substantial Holding
17/05/2004
 April 2004
Quarterly Cash Flow Report - Period Ended 31 March 2004
28/04/2004
Phase I Clinical Study - Advancing to Second Stage
27/04/2004
 March 2004
Starpharma Announces Institutional Share Placement
18/03/2004
PDF Status and Change of Name
18/03/2004
Starpharma Suspends Trading Pending Change of PDF Status
16/03/2004
 February 2004
Issue of Share Options to Prof Jean Fréchet
9/02/2004
 January 2004
Update and Appendix 4C Quarterly Results for Period Ended 31 December 03
29/01/2004
Starpharma PDF Status
23/01/2004